Bibliography
- King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011;378(9807):1949-61
- Kropski JA, Lawson WE, Young LR, Blackwell TS. Genetic studies provide clues on the pathogenesis of idiopathic pulmonary fibrosis. Dis Model Mech 2013;6(1):9-17
- Anon, American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161(2 Pt 1):646
- Shah NR, Noble P, Jackson RM, et al. A critical assessment of treatment options for idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 2005;22(3):167-74
- Adamali HI, Maher TM. Current and novel drug therapies for idiopathic pulmonary fibrosis. Drug Des Devel Ther 2012;6:261-72
- Lu Y, Azad N, Wang L, et al. Phosphatidylinositol-3-kinase/akt regulates bleomycin-induced fibroblast proliferation and collagen production. Am J Respir Cell Mol Biol 2010;42:432-41
- Xia H, Khalil W, Kahm J, et al. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 2010;176:2626-37
- Cherry DK, Hing E, Woodwell DA, Rechtsteiner EA. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Report 2008(3):1-39
- Guan X-H, Lu X-F, Zhang H-X, et al. Phosphatidylinositol 3-kinase mediates pain behaviors induced by activation of peripheral ephrinBs/EphBs signaling in mice. Pharmacol Biochem Behav 2010;95(3):315-24
- GlaxoSmithKline Intellectual Property (No.2) Ltd. PI3K inhibitors for treating fibrotic diseases. WO117503; 2013
- GlaxoSmithKline Intellectual Property (No.2) Ltd. PI3K inhibitors for treating cough. WO117504; 2013
- SmithKlineBeecham Corp. Quinoline derivatives as PI3 kinase inhibitors. WO144463; 2008
- SmithKlineBeecham Corp. Quinazoline derivatives as PI3 kinase inhibitors. WO157191; 2008
- Knight SD, Adams ND, Adams JL, et al. Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 2010;1(1):39-43
- Munster PN, van der Noll R, Voest EE, et al. Phase I first-in-human study of the PI3 kinase inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors (study P3K112826). 2011 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2011;29(Suppl):3018
- Munster P, Specht J, Werner TL, et al. PI3K kinase inhibitor GSK2126458 (GSK458): clinical activity in select Patient (PT) populations defined by predictive markers (study P3K112826). Eur Soc Med Oncol (ESMO) 2012: abstract 1500
- Clinicaltrials gov. A proof of mechanism study with GSK2126458 in patients with Idiopathic Pulmonary Fibrosis (IPF). NCT01725139; 2013
- Conte E, Fruciano M, Fagone E, et al. Inhibition of PI3K prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms. PLoS One 2011;6(10):e24663
- Conte E, Gili E, Fruciano M, et al. PI3K p110gamma over expression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition. Lab Invest 2013;93(5):566-76
- Norman P. Evaluation of WO2012032067 and WO2012055846: two selective PI3Kdelta inhibitors, which is GSK-2269557? Expert Opin Ther Patents 2012;22(8):965-70
- Sriskantharajah S, Hamblin N, Worsley S, et al. Targeting phosphoinositide 3-kinase delta for the treatment of respiratory diseases. Ann NY Acad Sci 2013;1280:35-9